Tempus lab is a fast-growing technology firm that has built an operating system to battle against cancer disease. The primary mission is to redefine the use of clinical and molecular data in a healthcare setting. As the organization accumulates the collected data, the treatments of patients who come after diagnosis are advantaged because physician got useful tools from the previously received data.
Tempus is a rapidly growing company in Chicago that appeared in the top ten ranking, and as a matter of fact, it has built medical research labs for data analytics setup that requires medical professionals to operate. Tempus has raised $80 million in the fund round on March 2018, hence, bringing a total value of $1.1 billion to the company in a period less than one and half years. March rounds initiated by the new investors and the existing investors.
The organization estimates a total of $210 million investment in two years after being founded. New Enterprise Associates is the prominent investing company who has invested in firms co-founded by Lefkofsky and in the latest funds, Brad Keywell, a business partner and Revolution Ventures founder, Steve Case funded along with the Tempus co-founder.
Tempus has initiated a developmental program of building a database library which accommodates and make available of all enough resources for the medical researchers. Unicorn is an operational system for oncologists that enable physicians to use data to figure out cancer treatment process and extend that patients respond to a particular medicine.
Tempus employs about 100 expertise medical practitioners at its River North headquarters and aims at increasing the number by recruiting more software engineers and computational biologists. This healthcare firm contains a genomic sequencing technology lab that processes more than 50,000 patients annually.
Tempus Unicorn has partnered with cancer research hospitals like the Mayo Clinic, the Cleveland Clinic, Northwestern University, the University of Michigan, the University of Chicago, Duke University School of Medicine, Knight Cancer Institute, and the UC Davis Comprehensive Cancer Center. The traction that Tempus made with others in the industry has been well as it currently works with nearly half of all Academic Medical Centers in the United States.
Tempus is a Chicago based technology company founder in the year 2015. It is building the world’s most extensive library of molecular, clinical data and an operating system to make that data most useful and accessible. We equip our physicians with skills to deliver personalized cancer care for patients through the interactive analytical and available machine learning platform.
Unicorn Company offers genomic sequencing services, therapeutic and analyzed molecular data to empower our physicians in making real-time and data-driven decisions. Physicians receive better tools to learn as the organization gathers more data purposely to benefit cancer patients.
Tempus on 20th March 2018 announces through Chicago news magazine announced that it had raised $80 million more funds in financing development projects. The round comprised of New Enterprise Associates, the existing investors, and new investors Kinship Trust Company. Rowe T. Price Associates, Inc. advised these funds. The foundered firm has raised funds amounting to $210 million in all funding to date. Additional funds are set to scale and further growth of the Tempus’ clinical and molecular analytic platform.
Tempus experienced challenging factors with the health care system before attaining its strength where useful data and real-world evidence got wasted. Eric Lefkofsky, the co-founder and the Chief Executive Officer of Tempus stated that the company is in an excellent position to usher in the era of precision medicine to help cancer patients only when given the scale and breadth of current data set.
The organization finds it hard to scale efforts of cancer treatment without centralizing large amount of therapeutic, phenotypic and molecular data because of isolated personalized medicine. Tempus has strived to solve this issue by building a stable ecosystem to collect, sort, analyze, and apply data solutions to healthcare and oncology through a suite of products that control clinical decision support and cutting-edge research.
Apart from working with independent oncologists, The company has also partnered with several cancer research hospitals like the University of Michigan, Mayo Clinic, University of Chicago, Northwestern University, the Cleveland Clinic, Duke University School of Medicine and Knight Cancer Institute. Tempus Unicorn currently works with nearly half of Academic Medical Research Centers in the United States.
Dr. Clay Siegall is the co-founder, and President of Seattle Genetics. Dr. Siegall used innovative ideas, thorough research and drug development in order to find ways to cure patients with cancer. With the help of Dr. Siegall, Seattle Genetics (publically traded on the NASDAQ Market), has capital-raising activities set over $675 million- this includes private and public financings. This company is the leader in what is known as “antibody drug conjugates” (ADC) to fight cancer. ACETRIS was the first product created by the ADC method. It was approved by the FDA in 2011. ACETRIS is available in over 50 countries around the world. Thanks to ADCETRIS, more than 15,000 lymphoma patients have found treatment. This treatment is even being used to help patients with Hodgkin’s lymphoma that may relapse. Along with ADCETRIS, Seattle Genetics is working on other clinical-stage programs. This includes SGN-CD33A for acute myeloid leukemia. Also, SGN-CD19a, is likely to be used for non-Hodgkin lymphoma.
Clay Siegall’s goal is to kill only malignant cells, since chemotherapy can kill healthy cells in the process. Also, malignant cells can build a resistance, making it harder for the cancer to be terminated in the body. The goal is to keep the patient cancer-free, only sacrificing cancerous cells in the process.
Seattle Genetics was founded in 1998 in a suburb known as Bothell, Washington, North of Seattle. Along with serving as President of Seattle Genetics, Dr. Siegall is on the Board of Directors for Ultragenyx Pharmaceutical (since January 2014), Alder Biopharmaceuticals, Inc (Since 2006), and Mirna Therapeutics Inc. (Since 2013). Dr. Siegall has received his Bachelor of Science (Zoology) from the University of Maryland. He received his Ph.D (Genetics) from the George Washington University. Seattle Genetics, the company’s goal is to “make a difference in the life of cancer patients”. The company has over 650 employees.